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Abstract
Background: Heparin exposure and device-related thrombocytopenia complicate the diagnosis of heparin-induced
thrombocytopenia (HIT) in patients receiving mechanical circulatory support (MCS). To improve anticoagulation
management for patients with newly implanted MCS devices, incidence of confirmed HIT needs to be further
characterized. Objectives: The purpose of this study is to describe the incidence of HIT and clinical utility of the
4Ts score in patients with newly implanted MCS devices. Methods: This is a retrospective analysis of MCS patients
receiving unfractionated heparin from 2014 to 2017. The primary end point was incidence of laboratory-confirmed
HIT. Strong positive, likely positive, low probability, and negative HIT categories were established based on heparininduced platelet antibody (HIPA) and serotonin release assay (SRA). Secondary end points include characterization of
platelet trends, argatroban use, incidence of HIT among each of the MCS devices, and utility of 4Ts score. Results:
A total of 342 patient encounters met inclusion criteria, of which 68 HIPA tests and 25 SRAs were ordered. The
incidence of HIT was 0.88% (3/342) and 4.4% (3/68) in patients with suspected HIT. Of the 68 HIPA tests, 3 (4.4%)
were considered strong positive and 3 of the 25 SRAs were positive. Median 4Ts score was 4 [2.5-4] and optical
density 0.19 [0.11-0.54]. The positive predictive value for the 4Ts score was 0.15 (CI = 0.03-0.46) and negative
predictive value, 0.93 (CI = 0.82-0.98). Conclusion and Relevance: HIT occurs infrequently with newly implanted
MCS devices. The 4Ts score appears to have a high negative predictive value for ruling out HIT.
Keywords
heparin-induced thrombocytopenia, unfractionated heparin, 4T-score, percutaneous mechanical circulatory support,
ventricular assist device, extracorporeal membrane oxygenation

Introduction
Mechanical circulatory support (MCS) devices are frequently used for temporary or permanent hemodynamic
support in patients with cardiogenic shock or end-stage
heart failure.1,2 Despite their ability to provide life-sustaining hemodynamic support, MCS devices are associated
with serious hematologic complications, including hemorrhage, hemolysis, thrombocytopenia, and thrombosis.2-4 In
particular, thrombocytopenia can be directly related to the
anticoagulation therapy required to prevent thrombotic
complications. Because of its short duration of action and
reversibility, unfractionated heparin (UFH) is the most frequently used anticoagulant in the acute setting during MCS

implantation.5 A serious adverse effect associated with UFH
is heparin-induced thrombocytopenia (HIT), which can
develop in 0.1% to 5% of patients.6 Anti-PF4/heparin antibodies are detected in 25% to 50% of post–cardiac surgery
patients; however, only 1% to 3% are reported to have clinically relevant HIT.7,8 When HIT is suspected, an alternate
nonheparin anticoagulant such as a direct thrombin
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inhibitor (DTI) can be used until the diagnosis of HIT can
be ruled out or confirmed.9
Differentiation between MCS device–related thrombocytopenia and HIT is challenging, and limited literature
exists to assist clinicians in this scenario.3 Patients who
require MCS devices are at risk for the development of HIT
because of high doses of heparin administration during
implantation and prolonged infusion of UFH to prevent
thrombus formation. Therefore, it is critical to identify the
true incidence of HIT and when to modify anticoagulation
therapies to provide safe and effective care for critically ill
patients. Clinical prediction tools such as the 4Ts score exist
to predict HIT but were not designed for patients being
treated with MCS devices.10,11 There are limited data on
assessing the predictive value of the 4Ts score in patients
being treated with MCS.12,13 This study aims to evaluate the
incidence of acute HIT in patients with newly implanted
MCS devices receiving UFH and characterize the 4Ts score
in predicting HIT in the study population.

Methods
This was a retrospective study conducted at a tertiary
care center. Patients were included if they were ≥18 years
old and admitted to the cardiovascular intensive care unit
from January 1, 2014, to January 1, 2017, and underwent
placement of MCS requiring anticoagulation with UFH.
The MCS devices utilized included durable left ventricular
assist devices (LVADs), such as the HeartMate II and
HeartMate 3 (Abbott, Pleasanton, CA), HeartWare
(HeartWare, Miami Lakes, FL), percutaneous ventricular
assist devices (PVADs) such as CentriMag (Abbott,
Pleasanton, CA), TandemHeart (CardiacAssist, Pittsburgh,
PA), Impella (Abiomed, Danvers, MA), and venovenous,
and venoarterial, extracorporeal membrane oxygenation
(ECMO). Included patients were grouped into the suspected
HIT group if they had a heparin-induced platelet antibody
(HIPA) or serotonin release assay (SRA) result and the HIT
not suspected group if the assays were not ordered. The
HIPA or SRA were ordered by the treating clinician based
on clinical suspicion and trends of platelet reduction from
baseline. Patients were excluded if they had a documented
history of a heparin allergy or were pregnant. The study was
approved by the institutional review board.
The primary outcome was to describe the incidence of
laboratory-confirmed HIT in the study population. Laboratory
assays used to confirm the diagnosis of HIT included the
HIPA (PF4 ELISA, Immucor) and SRA. The PF4 ELISA
reports optical density (OD) to predict the likelihood of
developing HIT antibodies. An OD of ≥0.4 is considered
positive and SRA is positive if ≥20% of serotonin release
occurred with low-dose UFH exposure. Because SRA is the
gold standard for diagnosis of HIT, a positive SRA regardless
of OD was considered positive. In the case where SRA was
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not available, OD was used to determine the presence of
HIT antibodies. Patients were categorized into 4 groups of
describing the likelihood of HIT using quantitative interpretation of OD and SRA measurements from a previous
study.14 The following definitions were used to define HIT:
strong positive (SRA positive and/or OD ≥2), likely positive (OD = 1.01-1.99), low probability (OD = 0.41-1), and
negative (OD ≤0.4 or negative SRA). Patients who met the
definition for strong positive were included in the primary
analysis for incidence of HIT. Secondary objectives include
comparing the overall incidence of thrombocytopenia
(platelet < 100 × 103/µL) and platelet trends between
patients who had suspected HIT and those who did not have
suspected HIT, evaluating the utility of the 4Ts score, and
describing the use of DTI in the study population.
Data collected include baseline demographic information, platelet count (on admission or at baseline defined as
last normal value within the past 100 days, and up to 14
days post–device implantation), IV UFH, and DTI orders
(dosing and duration). Because of poor documentation of
4Ts scores in the medical record, the investigators retrospectively collected the 4Ts score for each patient who had
the HIT panel or SRA ordered. Two investigators collected
4Ts scores for patients and used the same data collection
template for consistency. The 4Ts score was calculated on
the first date the HIPA panel and SRA were ordered. If the
assays were ordered on separate dates, the 4Ts score was
calculated on the date the first assay was ordered. The lowest platelet count for each patient was included for each day
post–device implantation for 14 days. Any subjective determination of 4Ts score, that is, other causes of thrombocytopenia or thrombosis, only incidents documented in the
patient’s chart was counted. The study categorized the likelihood of HIT based on the 4Ts score into low probability
(score < 4) or moderate to high probability (≥4).
Categorical variables are presented as n (%). Continuous
variables are presented as means (SDs) or median (interquartile range), as appropriate.

Results
A total of 1102 hospital admissions were screened resulting
in 335 unique patients meeting study inclusion criteria and
342 hospital encounters (Figure 1). The median age of the
population was 62.6 years [52.8-70], and there were 123
Impella, 91 LVADs, 60 ECMO, 14 PVADs, and 54 patients
receiving MCS device support with more than 1 device.
Additional demographic characteristics are listed in Table 1.
A HIPA with OD, SRA, or both labs were ordered in 68
encounters suspected to have HIT by the primary team.
Three patients met the definition of strong positive HIT.
Therefore, the overall incidence of HIT for the entire study
population was 0.88% (3/342 encounters). In patients with
suspected HIT, the incidence was 4.4% (3/68) with a median
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Figure 1. Inclusion and exclusion criteria.

Abbreviations: ECMO, extracorporeal membrane oxygenation; LVAD, left ventricular assist device; MCS, mechanical circulatory support; PVAD,
percutaneous ventricular assist device.

Table 1. Baseline Characteristics.
Characteristics
Age (years), median (IQR)
Male, n (%)
Length of stay (days), median (IQR)
Device type, n (%)
Impella
ECMO
LVAD
PVAD
>1 Device
Duration of MCS device (days), median (IQR)
Impella
ECMO
LVAD
PVAD
Baseline platelet (×103/µL), median (IQR)

n = 342
62.5 (52.6-70.2)
222 (66.3)
18.9 (7.0-31.2)
123 (36)
60 (17)
91 (27)
14 (4)
54 (16)
4 [2, 6]
8.79 [4, 11.15]
N/A
2.88 [1, 23.9]
204 (162-260)

Abbreviations: ECMO, extracorporeal membrane oxygenation; IQR,
interquartile range; LVAD, left ventricular assist device; MCS, mechanical
circulatory support; PVAD, percutaneous ventricular assist device.

OD of 0.19 [0.11-0.54]. The HIPA was ordered on median
day 3 [1-5] from device implantation.
Of the 68 HIT tests, 62 were negative, 3 were low probability of HIT with ODs of 0.41 to 1, and 3 were strong
positive based on SRA (Table 2). A single patient with
strong positive HIT was in each of the ECMO, Impella, and
PVAD subgroups. There were 15 patients with ODs of 0.41
to 1, of whom 12 had negative SRA. Three patients did not
have SRA sent and were included in the low-probability

HIT group because we were unable to rule out HIT with
SRA. Even though 4 patients had ODs between 1.01 and
1.99, all 4 had negative SRA results and were, therefore,
categorized as negative HIT. A total of 25 SRAs were
ordered, of which 3 were positive.
The overall median 4Ts score for the suspected HIT
group was 2 [1-3]. For patients with strong positive HIT, the
median 4Ts score was 4 [2.5-4]. The median 4Ts score for
the low-probability HIT group was 3 [2-3], and it was 2
[1-3] for the negative HIT group. No patients were categorized as likely positive HIT because of confirmed negative
SRA. The sensitivity and specificity analysis of the 4Ts
score were 0.33 (CI = 0.06-0.76) and 0.82 (CI = 0.700.90), respectively. The positive predictive for the 4Ts score
was 0.15 (CI = 0.03-0.46), and negative predictive value
was 0.93 (CI = 0.82-0.98).
The percentage of patients who developed thrombocytopenia are presented in Figure 2. Significant thrombocytopenia seems to be present from day 1 to day 7 post–device
implantation, after which the prevalence decreased to less
than 20%. When platelet trend was analyzed between suspected HIT and no suspected HIT groups, thrombocytopenia
developed on postimplantation day 4 and recovered (defined
as platelet count > 100 × 103/µL) by day 9 in the suspected
HIT group (Figure 3). Of the patients with suspected HIT,
11 had had heparin exposure in the past 100 days.
Of the 68 encounters with suspected HIT, argatroban
was administered to 25 (36.8%) and was continued for a
median of 4 [2-13.25] days. Three of these patients were
found to have strong positive HIT, 0 had possible HIT, and
22 were later identified as negative HIT (88%). The median

4
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Table 2. Optical Density and Serotonin Release Assay Distribution.
Patients with suspected
HIT
Overall OD of 68
patients, median (IQR)
Negative HIT, n (%)
OD, median (IQR)
SRA ordered
  Negative, n
  Indeterminate, n
  Positive, n
Low probability, n (%)
OD, median (IQR)
SRA ordered, n
Likely positive, n (%)
OD, median (IQR)
SRA ordered
Strong positive, n (%)
OD, median (IQR)
SRA ordered, n
  Negative, n
  Indeterminate, n
  Positive, n

Total
(n = 68)

Impella
(n = 20)

ECMO
(n = 23)

LVAD
(n = 5)

PVAD
(n = 5)

>1 Device
(n = 15)

0.19 (0.11-0.54)
62 (91.2)
0.17 (0.11-0.38)
22
22
0
0
3 (4.4)
0.67 (0.64-0.71)
0
0 (0)
N/A
N/A
3 (4.4)
2.91 (1.7-3.06)
3
0
0
3

17
0.13 (0.1-0.54)
6
6
0
0
2
0.67 (0.64-0.71)
0
0 (0)

22
0.17 (0.11-0.35)
8
8
0
0
0 (0)

1
2.91a
1
0
0
1

0 (0)

1
0.50a
1
0
0
1

5
0.19 (0.18-0.67)
3
3
0
0
0 (0)

0 (0)

0 (0)

4
0.25 (0.12-0.47)
1
1
0
0
0 (0)

0 (0)

1
3.21a
1
0
0
1

14
0.17 (0.12-0.28)
4
0
0
0
1
0.67a
0
0 (0)

0 (0)

Abbreviations: ECMO, extracorporeal membrane oxygenation; HIT, heparin-induced thrombocytopenia; IQR, interquartile range; LVAD, left ventricular assist device; OD,
optical density; PVAD, percutaneous ventricular assist device; SRA, serotonin release assay.
a
IQR not calculated because only 1 patient met criteria.

OD for patients who received DTIs was 0.18 [0.113-0.519],
and 4Ts score was 2 [1-3]. All 3 patients who had a positive
SRA received argatroban.

Discussion
This retrospective analysis found that HIT was suspected in
19.9% (68/342) of patients receiving newly implanted MCS
devices, and the diagnosis was confirmed in 0.88% (3/342)
of patients. Among patients who had suspected HIT and
received testing, 4.4% (3/68) tested positive with SRA. A
previous study identified an incidence of HIT of 10.6%, as
defined by platelet activation in patients receiving MCS;
however, this investigation had a different study design and
collected a blood sample on all included patients on postoperative day 7.8 The difference in methods between studies
may explain the variation in HIT incidence because OD and
SRA testing were not completed in our study if clinical suspicion for HIT by the treatment team was low, as recommended by evidence-based guidleines.10
At our institution, if OD results are <0.4, it is recommended to discontinue DTI therapy and resume the patient
on UFH. However, if OD is ≥0.4, an SRA should be
checked for a more definitive diagnosis of HIT. A total of 25
patients in the present study with suspected HIT were initiated on DTI, and of those, 22 were later determined to be
negative for HIT. In all, 12 patients (48%) had an OD <0.4
and were continued on a DTI for a median of 2 days [1-4.5].

Of these 12 patients, 11 had a low-probability 4Ts score
and 1 had an intermediate-probability 4Ts score. This study
suggests that a greater emphasis may need to be placed on
clinical suspicion of HIT in conjunction with the 4Ts score
because of potential concerns about the validity of the
4Ts score in the studied population, as recommended by
experts.3 DTIs are prescribed when HIT is suspected despite
a low 4Ts score. This can be problematic because clinical
suspicion can vary between clinicians. Given the overall
low sensitivity and specificity seen with the 4Ts score, a
modified 4Ts score may be necessary to account for inevitable drops in platelets witnessed in those with MCS
devices, as previously described.12,13
The utility of the 4Ts score for HIT showed varying levels of sensitivity (33%) and specificity (82%) in the present
study. The results of the sensitivity and specificity analyses
are slightly different from those of a recent observational
study in patients with MCS devices, which concluded that
the areas under the receiver-operating characteristics curve
for the 4Ts score was 0.88 (CI 0.759-1.000).12 The optimal
cutoff score for the 4Ts score in this model was a value of 3.
However, most of the included patients had intra-aortic balloon pumps, whereas our patients received more complex
MCS devices. A second report noted that when using a
modified 4Ts score in the MCS population, the score had a
sensitivity and specificity of 77.6% and 57%, respectively.13
The current study reveals a high negative predictive value
of 93% in the MCS population, similar to a previous report
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Figure 2. Percentage of patients with thrombocytopenia post–device implantation.

Figure 3. Platelet trend between suspected heparin-induced thrombocytopenia (HIT) and no suspected HIT.

of a 90% negative predictive value in an MCS population.13
These findings support that a 4Ts score ≤3 may serve as a
useful tool for clinicians to rule out HIT. The thrombocytopenia and thrombosis that develop when utilizing MCS
devices are common device-related adverse effects that
may lower the 4Ts score’s positive predictive value.13

Using other clinical criteria such as persistent thrombocytopenia, a secondary fall in platelets after an initial
recovery, or thrombus development on therapeutic doses
of UFH may help guide clinical decision-making in the
absence of an accurate bedside tool to predict the presence of HIT.3

6
Thrombocytopenia is a common complication of MCS
devices, but little literature exists to describe the incidence.
Our study revealed that up to one-third of patients exhibited
thrombocytopenia in the first 5 days of device implantation
(Figure 2). The prevalence decreased to less than 20% by
day 8. In reviewing the platelet trend for study groups who
were categorized as suspected HIT and HIT not suspected,
we found that the median platelets for the HIT not suspected
group remained >100 × 103/µL and drifted upward for 14
days post–device implantation. These findings lend support
to the idea that the HIT not suspected group did not exhibit
platelet trends suggestive for HIT. For this reason, a HIT
panel was not sent. For the group with suspected HIT,
the platelets decreased to <100 × 103/µL near day 3 and
remained low until day 9. This coincided with the HIT panel
sent on day 3 [1-5] of device implantation. Because of the
low incidence of definite HIT, we hypothesize that the
thrombocytopenia is likely a consumptive process related to
the MCS devices rather than HIT.
In our study, 3 patients were diagnosed with definite HIT
confirmed by SRA. In the first case, the patient received
ECMO for 7 days and OD was ordered 2 days after beginning ECMO, which resulted in a value of 0.497. The patient
was diagnosed with acute left middle cerebral artery thrombus with cerebrovascular accident. The 4Ts score was 4.
The second patient had an Impella implanted for 11 days,
and OD was ordered 5 days after Impella placement, which
resulted in a value of 2.905. The calculated 4Ts score was 1,
and there was no evidence of thrombosis. The third case had
a TandemHeart implanted for about 14 hours. OD was
ordered the following day after device placement, and this
resulted in a value of 3.212. The patient was also found to
have a left ventricular apical thrombus. The calculated 4Ts
score was 4. In all 3 cases, argatroban was ordered at the
time of HIT suspicion and was continued for a total of 4 to
16 days. These cases highlight the clinical utility of early
HIPA testing if HIT is suspected based on high-risk characteristics because the SRA confirmatory testing may take 5
to 7 days.3 Assessment of the 4Ts score in the MCS population as a tool to predict the true presence of HIT may not be
adequately sensitive or specific.
There are limitations to this study. First, the retrospective
study design can affect the quality of the data through documentation errors within the electronic medical record. There
is a potential for calculating the 4Ts score differently among
the investigators even with prospective, randomized trials.14
The 4Ts score calculation is subject to different interpretations depending on the provider who is assessing the
patient.15 To mitigate this, standard data collection templates
were used to calculate 4Ts scores to minimize variations
among investigators. Investigators reviewed patients and
4Ts score calculation together as a group prior to data collection. In addition, the 4Ts score calculation was limited to
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only 2 investigators following the same criteria outlined in
the study protocol.

Conclusion and Relevance
The incidence of HIT in patients with newly implanted
MCS devices is low; yet a large proportion of patients with
thrombocytopenia received alternative anticoagulation. The
4Ts score seems to have a good negative predictive value
that may allow for its use to rule out HIT. Future research is
warranted to identify and validate an accurate bedside HIT
predicting tool in patients with MCS devices.
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